Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Regencell Bioscience Holdings Ltd files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Research and development
0.23
0.39
0.44
2.51
1.58
1.07
0.95
1.3
Selling and marketing
0
0.11
0
0.03
0.26
0.13
0.01
0.01
General and administrative
0.16
0.31
0.94
5.08
4.43
3.55
2.81
10.4
Operating expenses
0.39
0.81
1.38
7.62
6.27
4.74
3.77
11.7
Operating income
-0.39
-0.81
-1.38
-7.62
-6.27
-4.74
-3.77
-11.7
Interest income
0.01
0.09
0.25
0.19
0.02
Pre-tax income
-0.39
-0.81
-1.35
-7.59
-6.06
-4.36
-3.58
-11.7
Net income to minority interests
0.81
1.35
-0.15
-0.19
-0.06
Net income
-0.39
-0.81
-1.35
-7.45
-5.87
-4.3
-3.58
-11.7
EBITDA
-0.8
-1.35
-7.47
-5.98
-4.43
-3.69
-11.6
EPS, basic
0.21
0.34
-1.53
-1.19
-0.87
-0.72
-2.37
EPS, diluted
-0.21
-0.34
-1.53
-1.19
-0.87
-0.72
-2.37
Shares, basic (weighted)
0
3.78
3.78
4.84
494
494
494
495
Shares, diluted (weighted)
10
3.78
3.78
4.84
494
494
494
495
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
0.24
0.39
0.06
6.42
1.56
2.96
2.42
14.2
Short-term investments
10
10
5
2.48
Other current assets
0.01
0.03
0.06
0.15
0.01
0.03
Total current assets
0.39
0.07
16.4
11.6
8.11
4.9
14.2
Property, plant and equipment
0.11
0.08
0.71
0.44
0.14
0.22
0.14
Lease right-of-use assets
0.75
0.45
0.08
0.54
0.3
Total assets
0.51
0.34
18
12.6
8.44
5.76
14.7
Accrued liabilities
0.1
0.57
0.15
0.16
0.13
0.35
1.07
Total current liabilities
3.16
4.34
0.58
0.61
0.19
0.66
1.32
Lease liabilities
0.36
0.03
0.03
0.23
0.06
Total liabilities
3.16
4.34
0.94
0.63
0.22
0.9
1.38
Paid-in capital
0
0
28.5
29.4
29.9
30.1
50.3
Retained earnings
-2.65
-4
-11.4
-17.3
-21.6
-25.2
-36.9
Other comprehensive income
-0.09
-0.05
-0.06
-0.05
Shareholders' equity
-1.84
-2.65
-4
17.1
12
8.22
4.86
13.3
Minority interests
0.02
-0.04
Total equity
-1.84
-2.65
-4
17.1
12
8.22
4.86
13.3
Total liabilities and equity
0.51
0.34
18
12.6
8.44
5.76
14.7
Shares outstanding
3.78
3.78
4.92
13
494
494
496
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-0.39
-0.81
-1.35
-7.59
-6.06
-4.36
-3.58
-11.7
Depreciation and amortization
0.01
0.03
0.15
0.29
0.31
0.08
0.08
Stock-based compensation
0.92
2.76
0.92
0.45
0.24
3.23
Cash from operations
-0.39
-0.73
-0.77
-5.27
-4.96
-4
-3.11
-7.7
Capital expenditures
-0.12
-0.78
-0.03
-0.01
-0.15
Purchases of investments
-10
-10
-5
-32.5
Cash from investing
-0.12
-10.8
0.06
5.24
2.69
2.5
Stock issued
18.6
Cash from financing
0.48
0.99
0.44
22.4
0.13
0.1
16.9
Exchange rate effect
-0.08
0.05
-0.11
0.02
Net change in cash
0.09
0.14
-0.33
6.36
-4.85
1.4
-0.54
11.8
Free cash flow
-0.84
-6.05
-4.99
-4.01
-3.27
Key metrics
Worked out from the statements above. Latest values use fiscal 2026. Valuation uses the share price of $5.23 on November 10, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-128.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-114.2%
Net income / average total assets.
Return on invested capital (ROIC)
-1,159.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
174.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
3.5%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
155.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
5.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
112.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
0.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
0.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
165.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
10.8x
Current assets / current liabilities.
Quick ratio
10.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
10.7x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$2.37
Net income per basic share, as reported (split-adjusted).
Operating cash flow per share
-$0.02
Cash from operations / diluted weighted shares.
Book value per share
$0.03
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
194x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
194x
Market cap / tangible book value, when positive.
Earnings yield
-0.5%
Net income / market cap (the inverse of P/E).
Was Regencell Bioscience Holdings Ltd profitable in fiscal 2026?
No. It reported a net loss of $11.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.